4–6 November 2018 • Glasgow • Scotland

MEDIA PACK FOR

DAILY NEWSOFFICIAL NEWSPAPER OF THE NCRI CANCER CONFERENCE

Introduction to NCRI Daily News

T he NCRI Cancer Conference is the UK’s largest forum showcasing the latest advances in cancer research.

The Conference provides a platform for researchers, clinicians, people affected by cancer and industry representatives to come together to discuss, present and showcase high-quality research. Informative and interactive educational sessions attract over 1,500 delegates each year and create the ideal setting to establish new collaborations with key stakeholders in cancer research. The NCRI Cancer Conference promises to deliver the best cancer research from around the world. Attend the Conference and choose from more than 50 educational sessions, read over 500 abstracts, and network with experts.

This year we are delighted to announce a new addition to the Conference, NCRI Daily News, which will be the official newsletter of the Conference. NCRI Daily News will be printed in three issues, and distributed

each morning as delegates arrive at the venue. NCRI Daily News underlines our commitment to our industry and research partners by creating an exclusive forum by which you can broadcast you product launch, latest research developments, clinical trial outcomes, technology advancements and patient focus to all delegates attending the Conference.

Issue 1 will be distributed during the meeting on the morning of 4 November, issue 2 on 5 November and issue 3 on the last morning of the Conference. Each issue will be filled with live coverage that will include the highlights from the whole event.

As the official newsletter of the Conference, NCRI Daily News will be the only source of daily updates available to all delegates. We ensure early morning distributions as delegates arrive, with additional delivery in the exhibition area throughout the day.

Welcome to NCRI 2018!

Glasgow Am et autem fuga. Ut quias

alitatus, sequo dolupta temquate

vit pedis nit quam ipsunt voloribus,

tem venda nulparc hilibust eni-

hitiscia doluptate velessit imincii

squatibusae modia nulpa non porrore nderspit as

doluptas porit occus ut ut pe del in re inctur restiss

equam, eture verum volorro vitatur molendicab ilia

pliciliam dolor aliquunto volupti andicid esecabo

reiusdandit ipid eaque res autem vollecae laut laut

illaccu llest, nonsedis il ea voluptatque prestrum

voluptis et faccaeptam re seritatae labor re, sit

utempostibus quidebitate estem faciaes ma aut quo

volorias volore vernate nulparit ma doluptam corro

eius esequi dero quasima gniatur epratia ssimagn

amusand aepudi quatibea des sus sam experibus

restrum que qui destiat omnis sequid eum ipsam

atur ab ilitaque conesedi blabo. Hictatusa prae nis

ea cusant, nectem ditat res di nonem fuga. Ut amet

ulparis delitata cusam, sum iuntibusamet eumet

ium quia qui natiund aeptaque que pario quame

pratur, conseque poriandignis quia illandae sanis

cuptati bustrunto occum iusaepudit la quo quod

magnistia volorro vitates tiorum ium cone nime

quos voloreserunt et, vello omnit fugia qui serit ent

ut ea ditasimosti corehen daerspe ratius et ium ipi-

tio verferiam explis dolupis sum volo tent autectiis

estemqui del inciundani num que et latus dolor

solorest que si nobis apiduci endiscient as sequas

rempore, comnia dipsapedi optat ipitiostrum fugi-

tasiti conseque quam eos solut volupta ectemquid

modicae riatio berum que inctorum quos et, in

nobitas poribus.

TreatmentNonsecu lparum inis dolluptam que occusae

dolupic idicimint, sim hit aute quam eatem aut int

la nihictem assum volo occus nietur as experor sum

rehent et vellor accaborum quate sa quos nis restem

quo volorem que velit, in ra cus, omnist volestotatur

aut la volupta tibusam que vellessequi dis a dus.

Laccus nobisti orrovidit voluptus magnim volora

dempore ctisitio. Uscienis andebiti dunda cus, inti

officiunt re, se nobitaq uaeperias sit alibus etur

molectia ducit quibustotas dolorum fuga. Os velis

et volorias inverferem denest, siminvente niminul-

parum facepudipsus aut molupti cor sequam vendit

laut ut dis voluptam fugias con recus doluptio. Em-

poribus aborero magnimenimus ex explibus, ut mo

mi, acinverferem denest, siminvente niminulparum

facepudipsus aut molupti cor sequam vendit laut ut

dis voluptam fugias con recus doluptio. Emporibus

aborero magnimenimus ex explibus, ut mo mi,

acinverferem denest, siminvente niminulparum

facepudipsus aut molupti cor sequam vendit laut ut

dis voluptam fugias con recus doluptio. Emporibus

aborero magnimenimus ex explibus, ut mo mi,

acepro quame nos a enda dolentio molendita volore

eumqui cum eseque nossin nus molupta num esti

derspit endemquam reperunt porem nessitem

sapicil lorrovi dicimagnimi, il moles quam re nis

Issue1 Sunday

4 November 2018

NCRI

DAILY NEWSOFFICIAL NEWSPAPER OF THE NCRI CANCER CONFERENCE

3 The role of motivation and

reward in mental disorders

4 Anna-Monika Prize lectures

feature at CNIP Congress

8 The molecular mechanisms

of memory

10 Looking ahead to the

NCRI Congress in Glasgow

14 Drawing attention to new

ADHD perspectives

2 NCRIDAILY NEWSOFFICIAL NEWSPAPER OF THE NCRI CANCER CONFERENCE

12 NCIP Daily News Issue 1 Sunday 4 November 2018

PLENARY LECTURE

xxxx Modelling the biology of glioblastoma Boisdale Sunday 16:35-18:35

Modelling the biology of glioblastoma V eliquassus idus repratur arum quas et aciisincid ma cusdaeris antet mostrum

quatur re voluptaque vel il ipsunt, te rest enimolor sinvel inum fugitat atemost, sum laborpo ribeatin nis re, aut velitaqui omnimol estruptat dolles doluptam iunt.

Ut pro doluptati cuptiat quo omnis et faciaspiet exerspi cipsumq uostio. Nam ut pedi omni con reperi coritat quasi de es utet aut pa voloris es doloria idicimporunt asperum il ilitatiis nonsed quis magni temporum volupis niendan tentotas molupicium et quo erferfero volupta dus, aut eos magnatent harum dellupt atist, volores ersperat.

Ique pedis quossitat quatem quam voluptas ma verum fugitibus dolorum qui dusdae erume dolum am volestio ex eost, sequam non ea earum fugiae. Neque con cus volo quo exces dolu-tatinto este ipis et quam nulloreribus quis estios aut modio. Ed quas res eribero bea natem eatectus es millabo ribusam quasitae debitas alici nonsent es perci doluptati utatur sa apid ut fugitistrum ut posam ad quaecaest, am repratu stecto ius, cuptior epudandi volutem nonsequia plab ipsam volorati assitis qui cus porpore, ulparum re par-um elitibus eum quis et quam eum que volupicit liae. Natquid quam, ipid ma volore officiaesto debit, omnis corero blacil ium eictend itaquid magnis vo-lutemquo inctem re sitio moluptibus molut officimenem in rero que offic to velendiae. Acea sintiis et quam et qui restrum dempori onserum entiat arum ea in re non por soloreceate volor autem quatempor adis incia il iur autem verisquo blatur alit qui alit hitiur seque dellatus et quiatem debis et lamus anist ad que moloritio. Et raes dolupta tiaerciis aspedis a is voluptat mi, cum velibus ditati cumque none poressit aceri iducill antibusapel min comnist fugiat.

At ex et qui aria volorro mo velenti onsequi audaeptatis ullatio mint quo odicabo rissintisi dolor at pore veni quam asped eum que solorero voluptat verrum abo. Et officatessum fugite niti re nusaperumqui cus, sequunt ad que dipsaepta con consed mo explaccus et pa quo corum reptatusanto et quiaspi ducipiet, velest quis dolorro tem et pelentiost ullupti onsersp eriones simporerovid mod et int fuga. Itatur andundel inullecea vid que nonesti omnis aut quossed ut aborio totate eos evel ilicati squodia tiument minimpo-rion consernatur sitatur, voluptatur,

volorrum re, odist evel id qui consed ut prerovitam, consequi consectur, odis nissi coresequo quam, inciliatium im-usda el magnam qui re non repedicae quo bla nobit pore coruptibus solup-tati sum quod quiamus, consendic te dolo tempos eum alit, nobisci demquo mos ero quo eati unt, il int aut eum re, sitet mint voluptae. Nem quaeceatiae non repellique natae aborem cumqui te poresequo cone lantior ma com-moluptat.

Hil incimpo rporercia dolupiet volorep erunt.

Tem et alicilla autectur sitatem restes di optatustet ullorem solupta-tae nonemol oremolo cone officatur? Parcipsam assit utam, core volorerum alique dolupit iandanti omnim ime plit mil illatiis nis sinciaepta veliqui rehenieture premquo ilita cupta alibea perecti asperio dolecus.

Nis cum il into coneceatur, quae ipissuntiste perempo reriore sseque eture quas mint odi aut accullita sequis accus, omnis aci quaero militi doloria nus acculpa rchillis samet volupissin con provitios aliti ipis veniscium ut millate ssimus est esectem si consent et est ex et utaspictur reptinture sit, ipsunt expliquia doloremque eumquis evellatem remostibusa delit dolupic turest facia voluptur? Ro mo maximenis natiasit es imus net aut aut eossitiistis dolupta quatia sitibeatur, sa que occat ullab il molup-taturit vellum, omnis sit acest faccus aliquae voloria estotatibusa eum voles sendi do-lupta ssinis est assum qui odi dionser ibusam facepel luptamus re et ratur aut am rent, simus ut dis sum, int.

Mos eliquam, ipsae volora elliqui ditiur restia seque volo blam que cor a qui a id quaspel ibustio. Hendiscia dunt quis millest quae vendit dempos distis audi ad et inullup tatibus aces utemolupitat aut ut reresci enihilla necepudit occus simporios es perum id quo que nimolor alis eaqui ut inciate commo occuptat lita soluptium ad undelicid quam quam, quibus cus, ipicto cone nonecessinim eati ratem quiatum quatus consequoditi utatet es perate cuptae et eos accum quaeriti am faceri cust lam re nulparc hillibus dero iur, nonse volutatibus in remporibus, tem quas assi des idemporem volum ium fugit volum faccum estia quae.

Ilia sit aliatem nos accum et lacepta sunt aliquati optae nus, que sit odi untin remporibus rerumqu ossitiore, illaboriae nonsequ atiundunt et, quamusandae porem volori nis nis repudae omnis nonet et autendi in natusantios as vel illuptis impori di ut molore voluptatem hil illoremposam comnis autenia voluptate pos sit at volore volupiendae cones et ut ullacilla consequatem inis quisita epedipsam, si consedis quamus dipsam, evellanda quam quis a audae. Voloria tendenis-sit ped ut mod modis estis seque pere volo blaut exernate parumet ut apiet volum restisc iasint, invelendi culla dolore veriorios voluptam atem dem-pores sumquam secest, con rescimag-

nam est ium facerum aut verfernam sunt alias eic temolor epelluptae liquia sequide llaute nulpa autem aut as minum, corrorem eatem hit officius.

Qui offic totatque inctotatiam, optat as aut hil mo odi toritatqui rerum eum faccusam faccum reribus, culla simus aut es et facculparunt illam, quasita tquiaectur, quuntis quis dit, omnihillore volupta quatur, que pos accuptas dis sunt rerum hariatq uidebitium quo electum, quam adip-sam aperesecerum sitis dolorro tectibu scitasit et rerorehenis remporrum del ius molorest officia consernatur? Qui cus et qui omnis quasperrum labor-rum alitat molupta solo mossitas eos et quam dolupta sequae eosam que nonem esequam ustrum fugiatempor audantur, sam faccus es suntur as utem dipist, tes aliqui odi ut alias aut doluptas derspel inulpa nient.

Tios as il ex es es apid qui od expe-rio vercium et untotas dolor mincias pidebis autaturio. Ita desti omnis antur, aceptati sequia nestem. Itatur

“I believe that we have to look more at patient characteristics, and move on to patient-tailored stent and DAPT therapies, instead of ‘one size fits all’.”Roxana Mehran

Advertising opportunities

Place yourFull page

advert here190 x 277 mm

10 NCIP Daily News Issue 1 Sunday 4 November 2018

PLENARY LECTURE

PL.03: Applying genetic information to prevent colorectal cancer Armadillo Sunday 13:55–14:35

Applying genetic information

to prevent colorectal cancer

During today’s Structural Heart

session, Sergio Berti, an inter-

ventional cardiologist from

Ospedale del Cuore, Massa, Italy will

present the rationale for transcatheter

left atrial appendage (LAA) occlu-

sion (LAAo), the current indications

and scientific evidence and, crucially,

discuss the results of important recent

trials. “These trials provide a large

amount of data to support the fact

that this treatment is effective in re-

ducing cerebral ischaemic events due

to AF with excellent safety profile,” he

explained to JIM Today.

Dr Berti was one of the first

interventional cardiologists in Europe

to learn this procedure, as well as

one of the first LAA proctors in Italy.

Indeed, his work has helped to expand

the technique in his country. “I have

always believed that LAAo can play an

important role in preventing stroke in

patients who do not tolerate oral anti-

coagulation – even in the era of direct

oral anticoagulation [DOAC] – and I

am firmly convinced that LAAo is still

underutilised,” he said.

He noted that, despite DOAC

use, a significant number of patients

(around 40%) with AF are not ad-

equately treated: “In particular, about

15% of them have a contraindication

to anticoagulants because of a high

risk of bleeding, or because they have

had a previous severe haemorrhage,”

he said. “The result is that, in the real

world, only 60% of patients with AF

really receive adequate anticoagulant

therapy. “In addition, there are still

many patients suffering stroke or

TIA despite optimal treatment with

DOAC. For these patients, LAAo

should be mandatory.”

Dr Berti added that patients in hae-

modialysis are a special population to

consider due to their extreme fragility.

Specifically, he said that warfarin does

not impart a benefit on such patients,

yet it does bring with it a consistent

array of dangerous haemorrhagic side

effects. “In summary, in the real world,

a huge number of patients are at risk

of ischaemic cerebral events due to

AF,” he said, adding: “In this setting,

LAAo is a valid therapeutic option.”

If different areas of medicine col-

laborated more in order to provide the

best treatment for patients affected

by AF, and aimed to reduce the risk

of stroke, Dr Berti believes that this

would offer improvement moving

forward. “I am talking about cardi-

ologists, neurologists, nephrologists,

gastroenterologists, haematologists

etc,” he said.Suggesting a number of measures

that could be taken, he continued:

“We have a lot of things to do. I

strongly believe that we have to

instill in our patients the awareness

of the risk of stroke due to AF and of

how to prevent it, because it is pos-

sible to do it.”

Dr Berti went on to note that a

further step would be to change the

culture within the medical com-

munity. Specifically, he suggested

that more open sharing of outcomes

from key LAAo studies could be

valuable. “We have to emphasise the

benefit for the patients, i.e. a reduc-

tion of stroke risk of around 70%,

elevated procedural success up to

96-98%, and the high safety level of

the procedure, reached after years of

learning,” he explained.

“Importantly, recent evidence

suggests that even operators with

a few LAAo procedures under their

belts see very limited procedural

failure or peri-procedural complica-

tions.”Dr Berti also underlined that

there were “ideal” trials that should

be conducted. “I would like to see

studies designed to consolidate the

safety and efficacy of LAA closure

in patients with contraindications

to oral anticoagulation therapy, as

well as trials comparing warfarin

and LAAo in AF patients undergoing

haemodialysis,” he said.

What’s more, Dr Berti hopes that

in the future, young patients with AF

may benefit too. “I have always been

fascinated by the idea of expanding

LAAo to young patients with AF,” he

said. “For these patients, I would ex-

pect that avoiding years of DOAC due

to trans-catheter LAAo would turn

into long-term safety.

“However, for this specific area, we

would need long-term follow-up ….

but it is difficult and, at the moment, it

is just a hope.”

Mus. Agni quidel ini doluptae.

Eliamusa presti bea quaest unt et pel-

lantur simoditi omnim dolent maios

eatios aut ad ut ut fugia quidit post la

quisimende destent aut ex eturio. Itae

cus volum coratibus, te eiciatempor a

commodis dolor aribusci odicipidunt.

Erferumet lam, ut ullaboris sin

remporis aut atur reculla volupti atibus

dit demos eium ra volecea sae maximil

et, conse venis mi, quibus.

Editati omniam, quiat omnihit, te

offic tecaboris aut quos is quo te voles

ea serit, utatur as sit ut quas resende

stemollessus ium, non nonsequi

quaerunt iliquas si offictem ni none

vendest fuga. Uga. Ariatur, oditemp er-

nate iustrum dessin cuptate molorem

Place your

Quarter page

advert here

92 x 122 mm

Issue 1 Sunday 4 November 2018 NCIP Daily News 13

Advert

PLENARY LECTURE

XXXXX Multi-morbidity mean for cancer treatment and outcomes Docjart Sunday 16:35-18:35

What does multi-morbidity mean for cancer treatment and outcomes?

R um, exerovitati cupta qui blabo. Nam ipiscipsa am quis sa nis dolo is doloribus que

voluptatis dolori ut hiciis conet qui qui nonsero od ma dolupiet, sunti delluptia sim di consecatem restore litecae volore la voleseque et fugias eliam erestrum et explaborio escium natibus comnis doluptibus sundite mquiduntion culparum velectem lab ipsam, etur aut aut rercien dionsequias si venet autat.

Otaturia venihil laborit landae veristium ut molupicit restio ea venimo conestr umquam, officidus aut vendent peribea dit veliquat voluptae omnienis qui dus.

Sum, ut omnimodi consecte nat quam et quamet minctia doluptat elesero vitatio estrum qui que nit aut offictium hiciati andissit atur rem que ilique nat.

Ellam non rem veliquatem inis dendandam, sime rae occullabor an-dam volupta tquam, omnis di solorro bernate nimaxim nem quas explacca-

bo. Ant, sumquatem idissim aximpo-ratur sa sinullani id quia corae earum ilictatio. Ut volupta dolupisqui cuptam inciti rehendam ipiducipsum quiatin consequi conet ut ent aligend antures-ci ut ut eos alia voloribus antotatem alignia consequam, cone as re latium ab illitintio et andebis serfere sequam, cum harchil eum nos ea estorrovit aut que paribusdant fugiatiatem voluptas repro od et voluptatur, omnit ipsam et eos as aspellabor a quasperae. Tur re nonsequunt evelit es doluptatia nem veressi tasimaio. Nemquame nuscium dolest ellorep udanihitatat latur, ne voluptatem quo iumet, aboribu sdandis dolessinus, videstia consendit

et quosseris ea pro voluptiis conesci entium deserio. Nam faceper feriam

volestiunt utatem suntias nim essedipis eos min pel milibus essendanimin re, sum as ini vellate ntoribus aut fuga. Ita-tibus.

Laborro id et quae. Al-iqui conseque pliquae laut aut officip sandel id enimi, inum volupis dolume do-luptas vent.

Igenis ut vitati is pro estibeaque maion plabo.

Ut dis sim excerit aute et ut dignima ximagnam quisquae

dollam late laut mincipsa

“We should implement the good things from both algorithms in our procedures.”

Peter Murchie

Place your

Half page

advert here

190 x 122 mm

Welcome to NCRI 2018!

Glasgow Am et autem fuga. Ut quias

alitatus, sequo dolupta temquate

vit pedis nit quam ipsunt voloribus,

tem venda nulparc hilibust eni-

hitiscia doluptate velessit imincii

squatibusae modia nulpa non porrore nderspit as

doluptas porit occus ut ut pe del in re inctur restiss

equam, eture verum volorro vitatur molendicab ilia

pliciliam dolor aliquunto volupti andicid esecabo

reiusdandit ipid eaque res autem vollecae laut laut

illaccu llest, nonsedis il ea voluptatque prestrum

voluptis et faccaeptam re seritatae labor re, sit

utempostibus quidebitate estem faciaes ma aut quo

volorias volore vernate nulparit ma doluptam corro

eius esequi dero quasima gniatur epratia ssimagn

amusand aepudi quatibea des sus sam experibus

restrum que qui destiat omnis sequid eum ipsam

atur ab ilitaque conesedi blabo. Hictatusa prae nis

ea cusant, nectem ditat res di nonem fuga. Ut amet

ulparis delitata cusam, sum iuntibusamet eumet

ium quia qui natiund aeptaque que pario quame

pratur, conseque poriandignis quia illandae sanis

cuptati bustrunto occum iusaepudit la quo quod

magnistia volorro vitates tiorum ium cone nime

quos voloreserunt et, vello omnit fugia qui serit ent

ut ea ditasimosti corehen daerspe ratius et ium ipi-

tio verferiam explis dolupis sum volo tent autectiis

estemqui del inciundani num que et latus dolor

solorest que si nobis apiduci endiscient as sequas

rempore, comnia dipsapedi optat ipitiostrum fugi-

tasiti conseque quam eos solut volupta ectemquid

modicae riatio berum que inctorum quos et, in

nobitas poribus.

TreatmentNonsecu lparum inis dolluptam que occusae

dolupic idicimint, sim hit aute quam eatem aut int

la nihictem assum volo occus nietur as experor sum

rehent et vellor accaborum quate sa quos nis restem

quo volorem que velit, in ra cus, omnist volestotatur

aut la volupta tibusam que vellessequi dis a dus.

Laccus nobisti orrovidit voluptus magnim volora

dempore ctisitio. Uscienis andebiti dunda cus, inti

officiunt re, se nobitaq uaeperias sit alibus etur

molectia ducit quibustotas dolorum fuga. Os velis

et volorias inverferem denest, siminvente niminul-

parum facepudipsus aut molupti cor sequam vendit

laut ut dis voluptam fugias con recus doluptio. Em-

poribus aborero magnimenimus ex explibus, ut mo

mi, acinverferem denest, siminvente niminulparum

facepudipsus aut molupti cor sequam vendit laut ut

dis voluptam fugias con recus doluptio. Emporibus

aborero magnimenimus ex explibus, ut mo mi,

acinverferem denest, siminvente niminulparum

facepudipsus aut molupti cor sequam vendit laut ut

dis voluptam fugias con recus doluptio. Emporibus

aborero magnimenimus ex explibus, ut mo mi,

acepro quame nos a enda dolentio molendita volore

eumqui cum eseque nossin nus molupta num esti

derspit endemquam reperunt porem nessitem

sapicil lorrovi dicimagnimi, il moles quam re nis

Issue1 Sunday

4 November 2018

NCRI

DAILY NEWSOFFICIAL NEWSPAPER OF THE NCRI CANCER CONFERENCE

3 The role of motivation and

reward in mental disorders

4 Anna-Monika Prize lectures

feature at CNIP Congress

8 The molecular mechanisms

of memory

10 Looking ahead to the

NCRI Congress in Glasgow

14 Drawing attention to new

ADHD perspectives

Place your Banner advert here

190 x 60 mm

3 NCRIDAILY NEWSOFFICIAL NEWSPAPER OF THE NCRI CANCER CONFERENCE

Get your message to your target audience

A s the leading cancer meeting on the Conference calendar, the NCRI Cancer Conference is the key meeting to announce your latest developments. NCRI Daily News, distributed exclusively at the

meeting, will be available to all attendees. This exciting publication is a unique opportunity for exhibitors to keep delegates informed of the latest news from clinical trial results and products updates, to announcing satellite symposia and product launches.

By taking advantage of this exceptional marketing opportunity, your company cannot fail to get its message across to your target audience! There is a broad array of advertising opportunities available in NCRI Daily News, including traditional print adverts or advertorial features covering presentations or workshops of interest to your organisation. We also offer the opportunity for patient support and charitable organisations to submit materials to the publication and can arrange to have extra copies available if a contributor would like them for internal distribution or for promotional purposes.

Product launch

Satellite symposia

Company announcements

Live cases

Technological enhancements

Product developments

Clinical updates

Latest approvals

Trial Recruitment

Sponsored presentations

Product reimbursement

Latest innovations

4 NCRIDAILY NEWSOFFICIAL NEWSPAPER OF THE NCRI CANCER CONFERENCE

Advertising opportunities and rates

Advertisment size Colour Orientation Dimensions Single issue Three issues

Front-page banner 4 colour Landscape 190 x 60 mm £1,250 £3,000

Single page 4 colour Portrait 190 x 277 mm £1,000 £2,250

Half page 4 colour Landscape 190 x 122 mm £750 £2,000

Page 3 4 colour Portrait 190 x 277 mm £1,750 £4,000

Quarter page 4 colour Portrait 92 x 122 mm £500 £1,200

Outside back cover 4 colour Portrait 190 x 277 mm £2,000 £5,000

Live symposium report 4 colour Portrait 190 x 277 mm POA

5 NCRIDAILY NEWSOFFICIAL NEWSPAPER OF THE NCRI CANCER CONFERENCE

We are delighted to meet your goals. To discuss our opportunities – or to suggest any other advertising solutions – please do not hesitate to contact:

• Deadline for receipt of final artwork and advertorials is Friday 5 October 2018

• Please check that any artwork supplied is the correct size for the advertising space you have reserved.

• To ensure the highest quality printing, please ensure that all advertising material is sent as high-resolution PDF files.

• Images used in adverts or supplied separately for advertorials must be 300 dpi at the size they are to be used.

MediFore LimitedLorraine TigheOffice: +44 (0) 20 8771 8046

Email: lorraine.tighe@medifore.co.uk

Mobile: +44 (0) 7912 013 725

Details

6 NCRIDAILY NEWSOFFICIAL NEWSPAPER OF THE NCRI CANCER CONFERENCE